Clinical significance of interactions between clopidogrel and proton pump inhibitors;Znaczenie kliniczne interakcji miȩdzy klopidogrelem a inhibitorami pompy protonowej

Kardiologia Polska

Volumn 69, Issue 6, 2011, Pages 610-616

  Kubica, Aldona ^a   Koziński, Marek ^a   Grześk, Grzegorz ^a   Goch, Aleksander ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

DRUG INTERACTION; REVIEW; ARTICLE; DRUG EFFECT; HUMAN;

ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 79959319589     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Grześk G, Kubica A, Grześk E et al. Kwas acetylosalicylowy i klopidogrel w leczeniu choroby wieńcowej. Folia Cardiol Excerpta, 2009; 4: 310-316.
2. Bryniarski L, Pelc-Nowicka A, Zabojszcz M et al. Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies. Cardiol J, 2009; 16: 179-189.
3. Undas A, Stȩpień E, Branicka A et al. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol, 2009; 67: 591-598.
4. Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J, 2009; 157: 148.e1-e5.
5. Kubica J, Koziński M, Grześk G. Mechanizmy działania leków przeciwpłytkowych. Folia Cardiol Excerpta, 2009; 4: 10-17.
6. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol, 2008; 51: 256-260.
7. Kubica J, Koziński M, Grześk G et al. Inhibitory receptora płytkowego P2Y12. Folia Cardiol Excerpta, 2009; 4: 146-155.
8. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009; 374: 989-997.
9. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost, 2009; 101: 714-719.
10. Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol, 2009; 54: 1149-1153.
11. Neubauer H, Engelhardt A, Krüger JC et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol, 2010; 56: 91-97.
12. Angiolillo DJ, Gibson CM, Cheng S et al. Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clin Pharmacol Ther, 2011; 89: 65-74.
13. Zuern CS, Geisler T, Lutilsky N et al. Effect of comedication with proton pump inhibitors (IPPs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res, 2010; 125: e51-e54.
14. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937-944.
15. Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy, 2010; 30: 787-796.
16. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009; 180: 713-718.
17. EMEA statement on possible interaction between clopidogrel and proton pump inhibitors (http://www.npci.org.uk/blog//?p=354).
18. Tentzeris I, Jarai R, Farhan S et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost, 2010; 104: 1211-1218.
19. Sarafoff N, Sibbing D, Sonntag U et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost, 2010; 104: 626-632.
20. Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med, 2010; 152: 337-345.
21. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med, 2010; 363: 1909-1917.
22. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-710.
23. Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation, 2009; 120: 2322-2329.
24. Siller-Matula JM, Jilma B, Schrör K et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost, 2010; 8: 2624-2641.
25. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol, 2010; 70: 383-392.
26. Lee JK. Clopidogrel: IPP interaction more relevant in noncarriers of CYP2C19 loss-of-function gene (http://www.theheart.org/article/1120273.do).
27. Evaluation of the influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (SPICE) (http://clinicaltrials.gov/ct2/show/ NCT00930670).
28. Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. (DOSAPI) (http://clinicaltrials.gov/ct2/show/ NCT01175200).
29. Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 2010; 121: 512-518.
30. Kasprzak M, Koziński M, Bielis L et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J, 2009; 16: 535-544.
31. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol, 2010; 56: 2051-2066.